SCHEMBL2370518

SCHEMBL2370518

CC(C)(C)OC(=O)N1CCc2sc(N3CCOCC3)cc2C1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 1/20 0.54
NR1H2 P55055 1/20 0.47
USP2 O75604 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
BRD4 O60885 1/20 0.46
CREBBP Q92793 1/20 0.46
ADORA1 P30542 2/20 0.42
PIK3CA P42336 2/20 0.42
MTOR P42345 2/20 0.42
MAPT P10636 3/20 0.42
KDM4E B2RXH2 2/20 0.42
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.42
KMT2A Q03164 1/20 0.42
HDAC6 Q9UBN7 1/20 0.41
PRKDC P78527 2/20 0.41
RECQL P46063 1/20 0.40
MAPK1 P28482 1/20 0.40
GPR119 Q8TDV5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6423341 0.83 USP2 (0.49) ESR2NR1H2USP2SMN1; SMN2BRD4
SCHEMBL17385378 0.83 PRKDC (0.45) SMN1; SMN2PIK3CAMAPTKDM4EMEN1
SCHEMBL6421569 0.82 ESR2 (0.55) ESR2NR1H2BRD4CREBBPADORA1
SCHEMBL2921637 0.79 ESR2 (0.52) ESR2NR1H2USP2SMN1; SMN2BRD4
SCHEMBL12393136 0.79 ESR2 (0.52) ESR2NR1H2USP2SMN1; SMN2BRD4
SCHEMBL1017283 0.78 ESR2 (0.54) ESR2NR1H2BRD4CREBBPADORA1
SCHEMBL14876121 0.78 NR1H2 (0.60) ESR2NR1H2BRD4CREBBPADORA1
SCHEMBL22369230 0.78 ESR2 (0.54) ESR2NR1H2BRD4CREBBPADORA1
SCHEMBL32660197 0.78 ESR2 (0.54) ESR2NR1H2BRD4CREBBPADORA1
SCHEMBL6198277 0.78 NR1H2 (0.53) ESR2NR1H2USP2SMN1; SMN2BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220153756-A1 ANTI-INFECTIVE COMPOUNDS INSTITUT PASTEUR KOREA (KR) 2022-05-19 US disclosed
US-20170121349-A1 Anti-Infective Compounds INSTITUT PASTEUR KOREA (KR) 2017-05-04 US disclosed
WO-2015193506-A1 ANTI-INFECTIVE COMPOUNDS INSTITUT PASTEUR KOREA (KR) 2015-12-23 WO disclosed
EP-2545059-A1 A PROCESS FOR MAKING PRASUGREL Synthon BV (NL) 2013-01-16 EP disclosed
WO-2011110219-A1 A PROCESS FOR MAKING PRASUGREL SYNTHON BV (NL) 2011-09-15 WO disclosed
WO-2011110219-A1 A PROCESS FOR MAKING PRASUGREL SYNTHON BV (NL) 2011-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220153756-A1 ANTI-INFECTIVE COMPOUNDS RABGGTB, ELANE, SERPINB1 ESR2 3165/4885NR1H2 885/4885USP2 3826/4885
US-20170121349-A1 Anti-Infective Compounds FNTB, LSS, PGLS ESR2 3071/4885NR1H2 565/4885USP2 4482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.